Screening for Inherited Heart Disease - Full Text View

Purpose

Genetically inherited heart diseases like hypertrophic cardiomyopathy (HCM) are conditions affecting the heart passed on to family members by abnormalities in genetic information. These conditions are responsible for many heart related deaths and illnesses.

Presently, there are several research studies being conducted in order to improve the understanding of disease processes and symptoms associated with genetically inherited heart diseases.

This study is designed to determine the eligibility of patients diagnosed with or suspected to have inherited heart disease to participate in these research studies.

Condition

Heart Disease
Hypertrophic Cardiomyopathy

MedlinePlus related topics:

Cardiomyopathy Heart Diseases

U.S. FDA Resources

Study Type:	Observational

Official Title:	Evaluation of Patients With Known or Suspected Inherited Heart Disease (Screening Protocol)

Further study details as provided by National Institutes of Health Clinical Center (CC):

Study Start Date:	April 1998
Estimated Study Completion Date:	April 2003

Detailed Description:

Patients with hypertrophic cardiomyopathy (HCM) and other inherited cardiac diseases are being studied under several research protocols to determine their pathogenesis and clinical manifestations. The purpose of this protocol is to determine the eligibility of patients with known or suspected inherited heart conditions for our research protocols.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA

Subjects and family members known or suspected to have inherited a cardiac disease such as HCM.

EXCLUSION CRITERIA

Patients with cardiac conditions that are not known to be inherited.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001746

Locations


United States, Maryland
	National Heart, Lung and Blood Institute (NHLBI)
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

More Information

Publications:

Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987 Mar 26;316(13):780-9. Review. No abstract available.

Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995 Oct 1;92(7):1680-92. Review.

Solomon SD, Jarcho JA, McKenna W, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990 Sep;86(3):993-9.

Study ID Numbers:	980102, 98-H-0102
First Received:	November 3, 1999
Last Updated:	March 4, 2008
ClinicalTrials.gov Identifier:	NCT00001746
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Hypertrophic Cardiomyopathy

HCM

Evaluation for Research

Medical Advice

Study placed in the following topic categories:

Pathological Conditions, Anatomical

Hypertrophy

Heart Diseases

Cardiomyopathy, Hypertrophic

Constriction, Pathologic

Aortic valve stenosis

Aortic Valve Stenosis

Cardiomyopathies

Heart Valve Diseases

Additional relevant MeSH terms:

Aortic Stenosis, Subvalvular

Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001746